Rob Taaffe’s Post

This Rare Disease Day (29th February), we are hosting an exciting webinar, which will explore some of the opportunities and challenges of launching orphan medicines in secondary markets. My colleague, Robert Taaffe (Consultant – Global Market Access), will present his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates. We will contrast this with Michelle James' (Associate Consultant – Global Market Access) research into market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions, specifically Denmark, Sweden, and Norway. We will explore these contrasting regions to showcase the significant differences between markets when it comes to: ➡️ Overall and rare disease patient populations ➡️ Access inequalities ➡️ Time to diagnosis ➡️ Access to innovation timelines ➡️ Healthcare funding ➡️ Health technology assessment frameworks I will then lead a discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy. Learn more about this webinar at https://lnkd.in/egtmyZki If you can't make the date, please register and we'll send you a link to the recording shortly after the webinar: https://lnkd.in/eXiBxknG #raredisease #marketaccess #orphanmedicine #orphandrugs #Pharma #Nordic #MENA #rarediseaseday

Where will you be launching your new orphan medicine? This Rare Disease Day (29th February), join my colleagues from the Global Market Access team, as they compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions. Register now to join the live webinar at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February: https://lnkd.in/eP9HZDJM Our Global Market Access team will present their research into the market access conditions in the MENA region, with a focus on Egypt, Saudi Arabia, and the United Arab Emirates, as well as the Nordic regions, focusing on Denmark, Sweden, and Norway. After this initial comparison, they will discuss the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy. Learn more about this webinar at https://lnkd.in/eJr7zYqU If you can't make the date, please register and we'll send you a link to the recording shortly after the webinar: https://lnkd.in/eP9HZDJM #raredisease #marketaccess #orphanmedicine #orphandrugs #Pharma #Nordic #MENA #rarediseaseday

Where will you be launching your new orphan medicine? This Rare Disease Day (29th February), join my colleagues from the Global Market Access team, as they compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions. Register now to join the live webinar at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February: https://lnkd.in/etFFKNbq Our Global Market Access team will present their research into the market access conditions in the MENA region, with a focus on Egypt, Saudi Arabia, and the United Arab Emirates, as well as the Nordic regions, focusing on Denmark, Sweden, and Norway. After this initial comparison, they will discuss the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy. Learn more about this webinar at https://lnkd.in/eZwetYFZ If you can't make the date, please register and we'll send you a link to the recording shortly after the webinar: https://lnkd.in/etFFKNbq #raredisease #marketaccess #orphanmedicine #orphandrugs #Pharma #Nordic #MENA #rarediseaseday

Where will you be launching your new orphan medicine? This Rare Disease Day (29th February), join my colleagues from the Global Market Access team, as they compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions. Register now to join the live webinar at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February: https://lnkd.in/edvbXgXJ Our Global Market Access team will present their research into the market access conditions in the MENA region, with a focus on Egypt, Saudi Arabia, and the United Arab Emirates, as well as the Nordic regions, focusing on Denmark, Sweden, and Norway. After this initial comparison, they will discuss the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy. Learn more about this webinar at https://lnkd.in/eiy3Tnpd If you can't make the date, please register and we'll send you a link to the recording shortly after the webinar: https://lnkd.in/edvbXgXJ #raredisease #marketaccess #orphanmedicine #orphandrugs #Pharma #Nordic #MENA #rarediseaseday

What an incredible conversation about 'RWE for Informed and Impactful Decision Making'! At the International Congress on Rare Diseases and Orphan Drugs, we explored how real-world data (RWD) can transform healthcare, especially for rare diseases. A huge thank you to our expert panelists: Patrice Verpillat (EMA), who highlighted the groundbreaking DARWIN EU initiative, demonstrating the power of collaboration to harness RWD's potential. Niklas Hedberg (TLV), emphasizing that RWD has the potential to democratize drug development by making data access less exclusive. @Stanislav Kniazkov (WHO Europe), underscoring that building trust – through technical standards, effective regulation, transparency and collaboration – is crucial for RWD to be used confidently in global policymaking. Sergio Diaz (IQVIA), championing patient-led data collection and advocating for patient organizations to play a leading role in shaping RWD initiatives. We heard perspectives from regulators, HTA bodies, global health leaders, and patient advocates. While RWD complements traditional clinical data, we need rigorous technological frameworks, quality standards, and agreement on their implementation to ensure it fulfills its promise. My key takeaway: The future of healthcare decisions lies in the responsible, collaborative, and technically robust use of RWD. Thank you to the organizers and my dear friend Dimitrios Athanasiou MBA for having me as a moderator and for a thought-provoking discussion! RARE DISEASES GREECE European Medicines Agency WHO Regional Office for Europe IQVIA #RWE #RareDiseases #DARWINEU #HealthcareInnovation

📅 Rare Diseases Forum 2024: securing Europe's competitiveness in research and development for people living with rare diseases. Register now to join Global Counsel on Tuesday, April 16 for a wide-ranging discussion convening policy makers, industry, patient organisations and academia for a series of panel discussions and keynotes focused on the EU's role in enhancing competitiveness in life sciences, fostering investment in the rare-diseases sector and examining the benefits of a competitive agenda for those living with rare diseases. Find out more about our speakers and programme, and register, at https://lnkd.in/dxufY4hJ. We are convening the Rare Diseases Forum on behalf of our event partners EURORDIS-Rare Diseases Europe, RARE DISEASES ORGANISATION BELGIUM, EFPIA - European Federation of Pharmaceutical Industries and Associations, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, EuropaBio - the European Association for Bioindustries, pharma.be, UCB, Novo Nordisk, Sanofi and Takeda.

🌟🌟 We are thrilled to welcome Ilias Pyrnokokis, Head of Value, Access & External Affairs, Chiesi Hellas, a distinguished expert in healthcare access at the upcoming International Conference on Rare Diseases and Orphan Drugs. 🌈🤝He will join the most awaited panel discussion on "Access and Reimbursement Strategies for Orphan Drugs in Europe" on [Friday 1st of March 🕒 14:30 PM - 15:15 PM] 🗓️ Digital. Along with our esteemed panelists he will delve into the challenges, opportunities, and innovative strategies shaping the future of rare disease treatments. 🌍 📌Ilias brings a wealth of knowledge and experience to our discussion on reshaping access and reimbursement strategies for orphan drugs in Europe. Join us as he shares invaluable insights, tackling the challenges and envisioning innovative solutions that can transform the landscape for rare disease patients. 💊 Don't miss this unique opportunity to gain valuable insights and network with industry experts. 🌐 Secure your spot! Registations are still open: https://bit.ly/3HkkWxA 🌍💙Spread the Word: Tag your network, colleagues, and anyone passionate about making a difference in the rare disease community. Let's amplify the impact of this panel discussion on a global scale! #ICORD2023 #rarediseasesconference24 #OrphanDrugs #RareDiseases #HealthcareAccess #PatientAdvocacy #IliasPyrnokokis

Here’s to another international medical research publication 💫 I am incredibly fortunate to have connected with an exceptional international panel of medical researchers and scientists for this much-anticipated and treasured publication in Open Forum Infectious Diseases Journal—the official journal of the Infectious Disease Society of America (IDSA). What was the best part of this research publication? Collaborating with some of the best researchers from across the globe, including experts from the USA, Dominican Republic, Indonesia, Nepal, and India! 🌍 This collaboration truly highlights the power of global teamwork in advancing infectious disease research. Excited to share our findings and be part of the ongoing work to enhance global healthcare! https://lnkd.in/dgrMX5Bt #ResearchCollaboration #InfectiousDiseases #GlobalHealth #OpenForumInfectiousDiseases #ProudMoment #MedicalResearch #IDSA #HealthcareInnovation #GlobalImpact #Pharmacology #Medical

In 2018, bioMérieux offered me the incredible opportunity to join the Global Health department and lead the Fleming Fund project. This marked the beginning of a personal commitment to deeply understand the complexities of antimicrobial resistance (AMR), the challenges faced by emerging countries, and how to better position bioMérieux's solutions to support the success of the Fleming Fund, with the unwavering support of our outstanding regional teams. Now, six years later, I look back with gratitude for the chance to collaborate with remarkable individuals across all the countries where the Fleming Fund entrusted us in Africa, in South Asia and in India and neighboring countries. I am particularly thankful for the shared dedication with local teams in the fight against AMR, and the tremendous collective efforts to make a meaningful impact. Among the many inspiring people I’ve encountered, two have been key in guiding our approach and strengthening our resolve to improve antibiotic usage, enhance microbiology expertise, and support clinicians in delivering better patient care. Last week, during multiple meetings held at the United Nations General Assembly in New York, a true zenith in global health discussions, I had the honor of meeting Dame Sally Davies for the first time and reconnecting with Tom Pilcher, with whom I’ve had the privilege of collaborating on numerous occasions. I am deeply grateful to bioMérieux for this journey and the opportunity to contribute to a cause that is critical to global health. However, the story is far from over—our fight against antimicrobial resistance continues. Together, we must carry forward the efforts we’ve made in these early years and remain steadfast in our mission to protect global health. #GlobalHealth #AntimicrobialResistance #AMR #AntibioticUsage #FlemingFund #bioMérieux #HealthcareInnovation #UNGA #UnitedNations #EmergingMarkets #PatientCare #Microbiology #AntibioticStewardship #FightAMR #PublicHealth #DameSallyDavies #TomPilcher

📢 As we forge ahead, it is crucial to remember that each partner in this journey brings unique strengths. By working in concert, we can strive towards a future where all people living with a #RareDisease have #access to effective #treatment and the hope for a better quality of life.   Read the op-ed our Secretary General, Alexander Natz, wrote for the Rare Disease supplement for The Parliament. Alexander urges a holistic and realistic approach to #OMP reform and action. Such approach must integrate diverse policy solutions under a unified vision through the product lifecycle and should be partnership-driven to transform the landscape of rare disease treatments and #research across #Europe. 👉 https://lnkd.in/dCf3TmNt #RDD2024 #RareDiseaseWeek #OrphanDrugs #Innovation #PatientAccess Takeda EURORDIS-Rare Diseases Europe